A Comparison of Long-Term Outcome in First-Episode Schizophrenia Following Treatment With Risperidone or a Typical Antipsychotic

Long-Acting Risperidone in Young Adults with Early Schizophrenia or Schizoaffective Illness

“…It has also been shown that symptomatically stable schizophrenia patients can be safely switched directly to longacting risperidone from both oral conventional antipsychotic medications (21) and conventional depot antipsychotics (13). The present results in young adults are compatible with these findings, and with those of studies of risperidone in first-episode psychotic patients (22)(23)(24)(25)(26). Long-acting risperidone was generally well tolerated in this study; movement disorder ratings (via ESRS scores) were very low throughout the trial The mean age of the young adults of this analysis-23 years-indicates that many would have been experiencing their first episode of psychosis when treatment with the previous oral or conventional depot antipsychotics was initiated.…”

Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies

“…This step led to the elimination of one 12-month double-blind, randomized trial comparing amisulpride (N=29) and haloperidol (N=31), as only four and nine patients in the respective treatment groups were free of tardive dyskinesia at study entry (of which one subject [25%] taking amisulpride and three subjects [33%] taking haloperidol subsequently developed tardive dyskinesia) (41). Also excluded was a report on two subgroups of 19 matched adults with first-episode schizophrenia treated for 1 year or longer with risperidone or various first-generation antipsychotics, which found no new cases of tardive dyskinesia, irrespective of treatment group (42). Furthermore, a publication by Tollefson et al (43) that reported tardive dyskinesia rates of 1.0% (annualized: 1.5%) for olanzapine and 4.6% (annualized: 8.3%) for haloperidol was excluded from this review because these raw incidences were based on the analysis of preliminary data for a smaller group of subjects than was described in a later publication by the same group (44).…”

Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

“…Comparative studies of atypical versus conventional antipsychotics in patients with first-episode psychosis demonstrate reduced extrapyramidal side effects and equal or slightly superior efficacy for the atypical antipsychotics (5)(6)(7)(8)(9)(10). First-episode patients respond to lower doses and demonstrate a greater sensitivity to antipsychotic treatment-related side effects (6,7,11) than do multiepisode patients.…”